Brain Scientific Inc. (BRSF) Poised to Solve Major Obstacles to Neurological Testing in Pediatric Patients

  • There is a significant need for EEG diagnostics in pediatric patients, but traditional testing is challenging due to poorly fitting adult-sized equipment, which also increases resistance to testing
  • This leaves a considerable gap in neurological care for young patients
  • BRSF’s Pediatric NeuroCap steps in to solve major barriers limiting EEG monitoring in pediatric care

There is a significant need for EEG diagnostics in pediatric patients, as children can suffer from neurological conditions, but traditional EEG procedure in this setting is time-consuming, cumbersome, and inconvenient. It means that the benefits of EEG testing in pediatrics could not be fully leveraged, leaving a considerable gap in neurological care for young patients. The gap that Brain Scientific (OTCQB: BRSF), a neurology medical device and software company, is poised to close.  

The most common neurological disorders in children include febrile seizures, which typically do not require EEG testing. However, for some other conditions, such as febrile status epilepticus, non-convulsive seizures, non-convulsive status epilepticus, and altered mental status of unknown cause, EEG testing is of critical importance. Sometimes, it is difficult to differentiate between the two groups of conditions with widely different outcomes. In many instances, EEG could help medical staff sort through complex differential diagnosis so that urgent treatment can be provided. Still, the logistical barriers to its use in pediatric emergency care often mean that medical professionals have to rely on indirect assessments instead. Fortunately, Brain Scientific is developing new technology that allows EEG to be deployed rapidly and accurately in children and adolescents (https://ibn.fm/iDOLU). 

Conducting EEG in ICU settings is often a practical challenge. For example, it requires that a portable EEG system is available or that the critically ill patient is transferred to an EEG suite. The latter could often have a detrimental health impact as it involves removing the patient in a severe condition from the urgent care support that serves as the lifeline for those in the most fragile state. It also requires trained EEG technicians to adequately position electrodes after applying gel to each, which takes considerable time. Time is incredibly precious in an urgent setting where every second counts —time spent on diagnosis eats away at the time that could be spent on treatment. 

It is even more of a struggle to deploy EEG in pediatric patients. A significant complicating factor for EEG testing in pediatrics is that adult equipment is often used for children. This means that it needs to be adjusted to fit a child’s considerably smaller head, which further complicates deployment as electrodes cannot overlap. Placing each electrode may turn into an even bigger challenge as children often resist medical testing. 

As much as traditional EEG testing is challenging in ideal circumstances, the pandemic has only exacerbated these struggles. The deadly virus can be found on various surfaces and equipment in a medical setting. Reusable EEG electrodes must be disinfected between uses to avoid cross-contamination between patients.  

This is where the Pediatric NeuroCap steps in to solve significant barriers limiting EEG monitoring in pediatric care (here is a video of the setup). Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific fully adapted its revolutionary NeuroCap to be used in children. The Pediatric NeuroCap comes in two sizes and includes 22 integrated, pre-gelled electrodes compliant with the 10-20 international system. 

With The Pediatric NeuroCap, the logistical struggle to perform EEG testing in pediatric patients appears on the way to be solved — the testing can be conducted within five minutes by any member of the clinical team. The cap removes the need to place each electrode one by one and is robust enough to sustain resistance to testing often found in pediatric patients. After delivering up to 4 hours of hospital-grade EEG monitoring, pediatric NeuroCap can be removed in less than 1 minute and disposed of, making it an ideal fit for the pandemic environment. The Pediatric NeuroCap is positioned to be the first disposable and pre-gelled headset available for the pediatric market, bringing faster, more efficient, and sanitary brain diagnostics to the pediatric setting.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050